Silence Therapeutics announced it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions and shareholder approval. While the filing also contains Q3 2026 financial results, the pending acquisition is the primary material event for investors.
Silence Therapeutics has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for approximately $1.3 billion in cash. Under the terms of the deal, Silence shareholders will receive $20.00 per ADS, representing a 130% premium to the company's recent closing price. The acquisition aims to strengthen Merck KGaA's specialty and rare disease pipeline, specifically incorporating Silence's Phase 2 siRNA candidate, Divesiran.
Value
$1.3B
Counterparty
Merck KGaA, Darmstadt, Germany
“We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, which is the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders.”
Iain Ross, Interim Principal Executive Officer and Chairman of the Silence Board
“The planned acquisition of Silence Therapeutics will strengthen our capabilities to serve patients with targeted specialty and rare diseases.”
Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany